Navigation Links
Ruthigen Reports Fiscal First Quarter 2015 Financial Results
Date:8/14/2014

the call.

About Ruthigen
Ruthigen is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications.  The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures.  The Company plans to complete its Phase 1/2 clinical trial in the first calendar quarter of 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials.  For more information, visit www.ruthigen.com.

About RUT58-60
RUT58-60 is a new chemical formulation containing hypochlorous acid, HOCl, with no hypochlorite, and utilizes other small molecule stabilizers.  RUT58-60 is a broad-spectrum anti-infective drug candidate designed for prophylactic use during invasive surgical procedures. RUT58-60 has been shown in laboratory tests to eradicate both gram-positive and gram-negative bacteria, including antibiotic resistant bacteria within the first 30 seconds of contact.  RUT58-60 was designed to improve patient lives, redefine infection control in surgical procedures and deliver cost savings to hospitals.  RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs.  The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery.  The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B. 

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and un
'/>"/>

SOURCE Ruthigen, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60
2. Perrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins. Conference call scheduled for 10 a.m. ET today.
3. Perrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins
4. CASI Pharmaceuticals Reports Second Quarter 2014 Financial Results
5. VirtualScopics, Inc. Reports Second Quarter and Six Months 2014 Financial Results; Awards Outstanding and Bookings Reflect a Two-Fold Increase Over 2013 First Six Months
6. PDI Reports 2014 Second Quarter Financial Results
7. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
8. Organovo Highlights Liver Toxicology Achievement, Reports Q1 Fiscal 2015 Results
9. Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update
10. Aratana Therapeutics Reports Second Quarter 2014 Results
11. Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Sage Analytics ( www.sageanalytics.com ), the developers of a ... announced its sponsorship of the California Cannabis Industry Association ... of tickets are available for groups or individuals to ... enjoying an open bar, buffet dinner and hors d,oeuvres, ... at sunset. With the legislative session in ...
(Date:8/3/2015)... , August 3, 2015 ... expected to reach USD 24.7 billion by 2022, ... Research Inc. Growing prevalence of neurological and musculoskeletal ... market over the forecast period. The presence of ... cryotherapy, advancement in the technologies coupled with implementation ...
(Date:8/3/2015)... SINGAPORE , Aug. 3, 2015 ... Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a ... today announced financial results for its first fiscal ... Quarter Highlights and Recent Developments: ... progress in improving its cost structure, driven by ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... INC. (Nasdaq: VION ) today announced that ... agent Cloretazine(R) (VNP40101M) in,acute myelogenous leukemia (AML) would ... of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago,Illinois., ... blind placebo-controlled,randomized phase III study of high-dose continuous ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 2Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting 3
(Date:8/3/2015)... ... 03, 2015 , ... According to an opinion piece published July 28 by the ... one pound of weight loss may not be accurate. While this system may work for ... of fat varies – based both on the individual and at what point that person ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... diseases researchers from the University of Pittsburgh School of Medicine are leading a ... prevention drugs in sub-Saharan Africa. , A cooperative agreement awarded by the ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... fitness site and the largest online retailer of nutritional supplements, has officially ... is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... TAMPA, Florida (PRWEB) , ... August 03, 2015 ... ... Association for Physician Leadership ® and Navigant Center for Healthcare Research and Policy ... nationwide. , Fifty-five percent of respondents said they agreed or strongly agreed that ...
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... VEGAS, Oct. 7 Cord Blood America, Inc. (OTC Bulletin ... ( http://www.cordblood-america.com ) focused on bringing the ... to families nationwide and internationally, said today that it has ... the third quarter of 2009. Total debt eliminated in ...
... The Ensign Group, Inc. (Nasdaq: ENSG ), announced ... skilled nursing and independent living campus, as well as ... acquisition was effective October 1, 2009. , (Logo: ... existing operational base and broaden our service offerings in ...
... LONDON and WASHINGTON, Oct. 7 Tranziger Limited announced ... team to advise and assess companies in the life ... realise and optimise value from their portfolios in these ... UK and has offices in Washington, DC and Edinburgh. ...
... ... Flexible Hypervisor Technologies Managed by Unified Set of Automation Tools Enable Profitable Cloud Services ... ... leader, Parallels , today announced enhancements to its server virtualization product portfolio to ...
... ... security landscape, endpoint security, and IT GRC with industry leaders , ... Scottsdale, AZ (PRWEB) October 7, 2009 -- As cybercrime ... organizations are faced with the challenge of staying ahead of these threats. To enable ...
... ... cancer research and support foundation. , ... Hampton Roads, Va. (PRWEB) October 7, 2009--October is breast cancer awareness month. Customer Magnetism, ... of funds from all new contracts signed and received during this month toward breast cancer ...
Cached Medicine News:Health News:Cord Blood America Announces Debt Reduction Tally: $8.7 Million in 2009; $3.7 Million in Third Quarter 2Health News:The Ensign Group Acquires Dallas Skilled Nursing Campus and Hospice Business 2Health News:The Ensign Group Acquires Dallas Skilled Nursing Campus and Hospice Business 3Health News:Tranziger Announces Formation of Global Advisory & Development Team 2Health News:Tranziger Announces Formation of Global Advisory & Development Team 3Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 2Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 3Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 4Health News:Parallels Server Bare Metal Launches, Building on Parallels' Containers Leadership to Enable Cloud Services Providers to Extend Virtualized Services 5Health News:Lumension Launches New Optimal IT Security Videocast Series 2Health News:Lumension Launches New Optimal IT Security Videocast Series 3Health News:Customer Magnetism Donates Funds In Support Of Breast Cancer Research 2Health News:Customer Magnetism Donates Funds In Support Of Breast Cancer Research 3
... The IX51 is an ... the observation and imaging needs ... applications. Modular design and the ... serve tasks from cell culture ...
... an innovative slider module for your fluorescence ... view fluorescence microscopy. The decisive step ... the new ApoTome, you can expand the ... neuro-, cell and developmental biology to exciting ...
... Nikon Instruments Inc., a world leader ... the introduction of its new Universal ... Nikon Eclipse upright microscope models, including ... This Universal Epi Illuminator provides ...
... Sonys new XCD-X710CR digital camera incorporates a ... offers excellent sensitivity (1024 (H) x 768 (V) ... with a color mask (commonly called a "Bayer ... in 8 or 10 bit to be converted ...
Medicine Products: